Genetic test-guided treatment for advanced bile and liver cancers
Part of Cancer, Digestive system clinical trials.
This study looks at using a genetic test (next-generation sequencing) to find cancer gene changes in stage IV hepatobiliary cancer. If there is a matching approved medicine, the study follows how well the “right drug for the right mutation” helps patients receiving palliative care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 65 and can give informed consent.
- You have stage IV hepatobiliary cancer confirmed by imaging and biopsy/pathology.
- You are choosing palliative care as the main approach (focus on comfort and control).
- Your genetic test must show a gene mutation that has a currently approved targeted medicine in China or the US.
- Your general health and daily functioning is fairly good (ECOG 0 to 2), and you’re expected to live at least 3 months.
- You must not meet major exclusions like severe organ problems, uncontrolled infections, or certain brain/heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment (BGB-B2033) for advanced liver cancer that has returned or not responded to previous immune therapy. It compares this new drug to the standard options sorafenib or lenvatinib, which are targeted pills. The goal is to see if BGB-B2033 can help shrink or slow the cancer better than the current treatments.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This study is testing whether combining targeted therapy with immunotherapy (or using two immunotherapies together) can help people with liver cancer that cannot be surgically removed. The goal is to understand how well these treatments work and how they affect biomarkers (signals in your body that show treatment response).
This trial is testing treatments that are customized to the specific genetic changes in your bile duct or gallbladder cancer. The goal is to find a drug that targets your tumor's unique mutation, which may help control the cancer better than a one-size-fits-all approach.
This study uses genetic testing of your tumor to find specific mutations and match you with targeted therapies, aiming to improve outcomes for advanced cancers with poor prognosis. If you have pancreatic, liver, or triple negative breast cancer and are starting treatment, this trial may help you access personalized treatment options.
This trial looks at how well a modern genetic test (next-generation sequencing) works when analyzing tissue samples from people with bile duct cancer. The goal is to see if this test can help doctors better understand these tumors.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.